Kalaris Therapeutics, Inc. KLRS
2.30 USD -0.12 (-4.96%)
At closeNov 9, 2026, 4:00 PM EST
2.30 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
2.28 Day range 2.50
1.78 52-week range 11.88
- YTD
- -72.75%
- 1 year
- -51.58%
- Market cap
- 54.75M
- EPS (ttm)
- -2.02
- YTD return
- -72.75%
- 1-year return
- -51.58%
- Volume
- 72.76K
- Avg volume
- 69.52K
- Open
- 2.49
- Previous close
- 2.42
- Day's range
- 2.28 – 2.50
- 52-week range
- 1.78 – 11.88
5D +0.36 (+17.48%)
Financials — quick view
KLRS Revenue — quarterly 0
KLRS Net income — quarterly -11.52M
KLRS EPS — quarterly -0.48
News
Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) Estimate - Kalaris Therapeutics Appoints Liisa Bayko CFO
Why Is Kalaris Therapeutics Stock Gaining Friday? 
12 Health Care Stocks Moving In Friday's Intraday Session 
Kalaris Therapeutics To Present Additional Data From Phase 1a Single Ascending Dose Trial Of TH103 In Neovascular Age-Related Macular Degeneration At ASRS Annual Meeting; On Track To Share Initial Data From Phase 1b/2 Study In H1 Of 2027 - Wedbush Initiates Coverage On Kalaris Therapeutics with Outperform Rating, Announces Price Target of $17
Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25
Your note
Sign in to keep a note on KLRS — it syncs with the Stock Master app.